Neural stem cells
derived from human pluripotent stem cells (hPSC-NSCs)
are of great value for modeling diseases, developing drugs, and treating
neurological disorders. However, manufacturing high-quantity and -quality
hPSC-NSCs, especially for clinical applications, remains a challenge.
Here, we report a chemically defined, high-yield, and scalable bioprocess
for manufacturing hPSC-NSCs. hPSCs are expanded and differentiated
into NSCs in microscale tubes made with alginate hydrogels. The tubes
are used to isolate cells from the hydrodynamic stresses in the culture
vessel and limit the radial diameter of the cell mass to less than
400 μm to ensure efficient mass transport during the culture.
The hydrogel tubes provide uniform, reproducible, and cell-friendly
microspaces and microenvironments for cells. With this new technology,
we showed that hPSC-NSCs could be produced in 12 days with high viability
(∼95%), high purity (>90%), and high yield (∼5 ×
108 cells/mL of microspace). The volumetric yield is about
250 times more than the current state-of-the-art. Whole transcriptome
analysis and quantitative real-time polymerase chain reaction showed
that hPSC-NSCs made by this process had a similar gene expression
to hPSC-NSCs made by the conventional culture technology. The produced
hPSC-NSCs could mature into both neurons and glial cells in vitro
and in vivo. The process developed in this paper can be used to produce
large numbers of hPSC-NSCs for various biomedical applications in
the future